Company Profile
Sagimet Biosciences Stock Price, News & Catalysts
- Ticker:
- SGMT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.62 USD (-4.85%)
Close
Last updated: November 19, 2026
419M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, SGMT closed down 4.85% at $9.62. No new same-company headline was identified in the current news window.
Company overview
Metabolic Pathway Therapeutics
Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.
Denifanstat
Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
Dermatology Focus
Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.
U.S. Acne Registration Strategy
Sagimet has initiated the U.S. AURORA Phase 3 program after positive denifanstat Phase 3 results from its Chinese license partner, while advancing a second FASN inhibitor into mid-stage acne development.
Future catalysts
- Initiation of a Phase 2 TVB-3567 study in moderate-to-severe acne by year-end 2026.
- Topline data from the U.S. Phase 3 AURORA study of denifanstat in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sagimet Biosciences (SGMT)?
Sagimet Biosciences (SGMT) most recently closed at 9.62 USD, a -4.85% move versus the previous session.
What is the market cap of Sagimet Biosciences (SGMT)?
Sagimet Biosciences currently has a market capitalization of 419M USD on BioPharmSignal.
What does Sagimet Biosciences do?
Metabolic Pathway Therapeutics Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production. Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology. Dermatology Focus Sagimet is prioritizing moderate-to-severe...
On which exchange is SGMT stock listed?
Sagimet Biosciences (SGMT) is associated with NASDAQ, United States, Biopharma.
What is TVB-3567?
Initiation of a Phase 2 TVB-3567 study in moderate-to-severe acne by year-end 2026.
Which conditions is Sagimet Biosciences targeting with TVB-3567?
Sagimet Biosciences is associated with metabolic disease, dermatology based on its company overview and current catalyst commentary.
How does Sagimet Biosciences describe recent progress with TVB-3567?
Initiation of a Phase 2 TVB-3567 study in moderate-to-severe acne by year-end 2026.
What is denifanstat?
Denifanstat Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
